VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Oral azacitidine plus CHOP for frontline PTCL treatment

Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, discusses a Phase II study (NCT03542266) aiming to evaluate the efficacy and safety of combined azacitidine and CHOP as initial treatment in peripheral T-cell lymphoma (PTCL) patients. The findings demonstrated that the addition of oral azacitidine to CHOP as initial therapy is feasible, safe, and induces high response rates in PTCL-TFH patients in particular. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter